Motoko Tachihara, MD, PhD; Kayoko Tsujino, MD, PhD; Takeaki Ishihara, MD, PhD; et al.
JAMA Oncol. 2023;9(11):1505-1513. doi:10.1001/jamaoncol.2023.3309
This single-arm, phase 2 nonrandomized controlled trial assesses the efficacy and safety of durvalumab with concurrent radiotherapy followed by durvalumab for treatment of patients with unresectable, locally advanced non–small cell lung cancer.
Burcu F. Darst, PhD; Ed Saunders, MRes; Tokhir Dadaev, MSc; et al.
JAMA Oncol. 2023;9(11):1514-1524. doi:10.1001/jamaoncol.2023.3482
This genetic association study examines the association between variants of established prostate cancer risk genes and the risk of aggressive prostate cancer.
-
Editorial
Rare Genetic Drivers of Lethal Prostate Cancer
Alexander W. Wyatt, BSc, DPhil
JAMA Oncol
Michael F. Gensheimer, MD; Harriet Gee, MD, PhD; Hiroki Shirato, MD, PhD; et al.
JAMA Oncol. 2023;9(11):1525-1534. doi:10.1001/jamaoncol.2023.3495
This nonrandomized controlled trial of patients diagnosed with non–small cell lung cancer assesses whether individualizing stereotactic ablative radiotherapy dose and fractionation by tumor size, location, and histological characteristics may be associated with local tumor control and the rate of toxic effects.
Marliese Alexander, PhD; Sam Harris, MBBS; Craig Underhill, MBBS; et al.
JAMA Oncol. 2023;9(11):1536-1545. doi:10.1001/jamaoncol.2023.3634
This randomized clinical trial evaluates whether a biomarker-driven, risk-directed approach to thromboprophylaxis would prevent thromboembolism among adults with lung and gastrointestinal (GI) cancers receiving anticancer therapies in ambulatory treatment settings.
Elizabeth M. Swisher, MD; Nadine Rayes, CGC; Deborah Bowen, PhD; et al.
JAMA Oncol. 2023;9(11):1547-1555. doi:10.1001/jamaoncol.2023.3748
This randomized clinical trial evaluates whether eliminating pretest and/or posttest counseling for home-delivered cancer risk assessment is noninferior with regard to participant distress.
-
Invited Commentary
Right-Sizing Models of Genetic Cancer Predisposition Testing
Huma Q. Rana, MD, MPH; Judy E. Garber, MD, MPH
JAMA Oncol
Oreste Davide Gentilini, MD; Edoardo Botteri, PhD; Claudia Sangalli, BSc; et al.
open access
has audio
JAMA Oncol. 2023;9(11):1557-1564. doi:10.1001/jamaoncol.2023.3759
This randomized clinical trial assesses whether the omission of sentinel node biopsy is noninferior to sentinel lymph node biopsy in female patients with small breast cancer and negative results on preoperative ultrasonography of axillary lymph nodes.
-
Audio:
Sentinel Lymph Node Biopsy vs No Axillary Procedure in Small Node-Negative Breast Cancer
Stuart J. Wong, MD; Pedro A. Torres-Saavedra, PhD; Nabil F. Saba, MD; et al.
JAMA Oncol. 2023;9(11):1565-1573. doi:10.1001/jamaoncol.2023.3809
This randomized clinical trial examines whether lapatinib combined with a cisplatin-based combination radiation regimen is effective for the treatment of patients with locally advanced head and neck cancer with poor prognosis.
Tae Won Kim, MD; Philippe L. Bedard, MD; Patricia LoRusso, DO; et al.
open access
JAMA Oncol. 2023;9(11):1574-1582. doi:10.1001/jamaoncol.2023.3867
This nonrandomized controlled trial evaluates the safety and antitumor activity of anti-TIGIT antibody tiragolumab and its combination with atezolizumab in patients with advanced solid tumors.
-
Editorial
Unlocking the Potential of Anti-TIGIT Therapy—Between Promise and Challenges
Joud Hajjar, MD, PhD, MS; Mohamed H. Derbala, MD; Aung Naing, MD
JAMA Oncol